KP415 oral capsule + Placebo oral capsule

Phase 3Completed

3 views this week 0 watching💤 Quiet

Interest: 34/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

ADHD

Conditions

ADHD

Trial Timeline

Dec 20, 2017 → May 16, 2018

NCT ID

NCT03292952

About KP415 oral capsule + Placebo oral capsule

KP415 oral capsule + Placebo oral capsule is a phase 3 stage product being developed by Zevra Therapeutics for ADHD. The current trial status is completed. This product is registered under clinical trial identifier NCT03292952. Target conditions include ADHD.

What happened to similar drugs?

10 of 20 similar drugs in ADHD were approved

Approved (10) Terminated (2) Active (10)

✅atomoxetineEli LillyApproved

✅Strattera (atomoxetine)Eli LillyApproved

✅Atomoxetine + placeboEli LillyApproved

✅Atomoxetine Hydrochloride + placeboEli LillyApproved

✅atomoxetine (Strattera)Eli LillyApproved

✅Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + PlaceboNovartisApproved

✅methylphenidate HCl ERCT + PlaceboPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03292952	Phase 3	Completed	Dec 20, 2017	May 16, 2018	ADHD

Competing Products

20 competing products in ADHD

See all competitors

Product	Company	Stage	Hype Score
atomoxetine	Eli Lilly	Approved	39
Strattera (atomoxetine)	Eli Lilly	Approved	43
Atomoxetine + placebo	Eli Lilly	Approved	43
Atomoxetine Hydrochloride + placebo	Eli Lilly	Approved	43
atomoxetine (Strattera)	Eli Lilly	Approved	43
Atomoxetine + stimulants (any approved ADHD medication)	Eli Lilly	Pre-clinical	26
dasotraline + Placebo	Sumitomo Pharma	Phase 3	40
dasotraline	Sumitomo Pharma	Phase 1	29
dasotraline 4mg	Sumitomo Pharma	Phase 3	40
AZD1446 + AZD1446 + AZD1446 + Placebo	AstraZeneca	Phase 2	35
Placebo + AZD3480 + AZD3480	AstraZeneca	Phase 2	35
MK0249 + Concerta (methylphenidate) + Placebo	Merck	Phase 2	35
Focalin XR	Novartis	Phase 3	40
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + Placebo	Novartis	Approved	43
Dexmethylphenidate HCl extended-release capsules	Novartis	Phase 3	40
Methylphenidate hydrochloride	Novartis	Phase 3	40
Focalin XR	Novartis	Phase 3	40
methylphenidate HCl ERCT + Placebo	Pfizer	Approved	35
methylphenidate HCl ERCT	Pfizer	Approved	35
Very Low Dose Quillivant XR + Low Dose Quillivant XR + Moderate Dose Quillivant XR	Pfizer	Approved	43